Tiziana Biagioli

Dr. Tiziana Biagioli

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MFMattia Fonderico
Mattia Fonderico
EPEmilio Portaccio
Emilio Portaccio
LRLorenzo Razzolini
Lorenzo Razzolini
LPLuisa Pastò
Luisa Pastò
ABAngelo Bellinvia
Angelo Bellinvia
MAMaria Pia Amato
Maria Pia Amato
The presence of intrathecal IgM synthesis (ITMS) has been associated with an aggressive multiple sclerosis (MS) clinical course. In the present systematic review, we aimed at assessing the prevalence of ITMS among different MS phenotypes. Moreover, we aimed at quantifying the risk of a second relapse in ITMS positive and oligoclonal IgG bands (OCGBs)-positive patients. We selected clinical studies reporting the ITMS prevalence assessed as oligoclonal IgM Bands (OCMBs), lipid-specific OCMBs (LS-OCMBs), and/or as an intrathecal IgM production > 0% (IgMLoc, Reiber formula). The overall prevalence of ITMS was higher in relapsing-remitting (RR) than clinically isolated syndrome (CIS) patients (40.1% versus 23.8%, p < 0.00001), while was in line with that detected in primary progressive MS (PPMS, 26.7%). Almost all patients (98%) with ITMS had also OCGBs. The risk of having a second relapse was higher in OCGBs positive patients (HR = 2.18, p = 0.007) but much higher in ITMS positive patients (HR = 3.62, p = 0.0005). This study revealed that the prevalence of ITMS is higher in RRMS patients. It suggests that the risk of having a second relapse, previously ascribed to OCGBs, may, to a certain extent, be related to the presence of intrathecal IgM.

3 July 2026 in Antibodies
Verified
Journal Article
Open access
PDF file
MAMarco Allinovi
Marco Allinovi
LMLuca Malatesta
Luca Malatesta
TBTiziana Biagioli
Tiziana Biagioli
EAElisabetta Antonioli
Elisabetta Antonioli
FPfederico perfetto
federico perfetto
Daratumumab, a human IgG1 monoclonal antibody targeting CD38, is widely used in multiple myeloma and AL amyloidosis. Despite its clinical success, many patients fail to achieve durable responses or relapse, underscoring the importance of understanding resistance mechanisms. Drawing on experience from other better-studied monoclonal antibodies, resistance to daratumumab can be categorized into four main mechanisms: (1) reduced CD38 expression on plasma cells; (2) increased expression of complement inhibitory proteins (CD55/CD59), impairing complement-mediated cytotoxicity; (3) reduced drug bioavailability due to urinary loss in non-selective nephrotic syndrome; and (4) the development of neutralizing anti-daratumumab antibodies. Anti-drug antibodies (ADAs) may represent a potential mechanism of treatment failure through effects on pharmacokinetics, efficacy, and safety, even in patients on daratumumab therapy. Seven different trials have tested anti-daratumumab antibodies. Among them, anti-daratumumab antibodies were identified in only 0–2.4% of patients, and only in a small portion of these has it been proven to be neutralizing. Overall, ADAs appear rare, but these findings are likely underestimated due to short follow-up and suboptimal timing of assessment. In conclusion, standardized ADA monitoring, particularly months after treatment interruption or in cases of inadequate response or infusion-related reactions, may improve patient management and therapeutic outcomes.

24 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MFMartina Focardi
Martina Focardi
BDBEATRICE DEFRAIA
BEATRICE DEFRAIA
IBIlenia Bianchi
Ilenia Bianchi
BGBarbara Gualco
Barbara Gualco
ACAndrea Costantino
Andrea Costantino
LLLuisa Lanzilao
Luisa Lanzilao
Background/Objectives: Accurate post-mortem interval (PMI) estimation remains challenging in forensic pathology. Although potassium (K+) is the most well-validated single biomarker in vitreous humor (VH), multivariate approaches may enhance precision by capturing the complex cascade of post-mortem biochemical changes. This study aimed to develop and validate a multivariate PMI estimation model incorporating three biochemical markers—potassium, ammonium (NH4+), and albumin (ALB)—in vitreous humor using automated clinical chemistry platforms for practical forensic application. Methods: Vitreous humor samples from 38 autopsy cases with documented PMIs (39.5–285 h; mean, 105.5 h) were analyzed for K+ (Cobas C8000), NH4+ (Cobas C8000), and ALB (Immage 800 nephelometry). Univariate and multivariate regression analyses were performed, with the residual standard error (RSE) as the primary measure of accuracy. Model validation was conducted by back-calculating PMI in four samples completely distinct from the training cohort. Results: All three analytes demonstrated strong individual correlations with PMI (R2: K+ = 0.88, ALB = 0.78, NH4+ = 0.69; all p < 0.001). The multivariate regression model [PMI = 40.25[Alb] + 0.01573[NH4+] + 5.339[K+] − 53.032] yielded an RMSE of ±15.5 h (MSE = 240.25 h2), outperforming potassium-only models (RMSE = ±22.6 h). Although NH4+ showed limited statistical significance in the multivariate model (p = 0.128), its inclusion improved overall predictive accuracy. External validation in an independent cohort of four subjects (distinct from the 38 subjects in the training set) demonstrated a mean absolute error (MAE) of 20.4 h. Conclusions: The multivariate approach combining K+, NH4+, and ALB in VH improves PMI estimation accuracy compared with single-marker methods. The use of automated clinical chemistry platforms enhances reproducibility and facilitates practical implementation in forensic laboratories.

24 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TBTiziana Biagioli
Tiziana Biagioli
LLLuisa Lanzilao
Luisa Lanzilao
FRfrancesca romano
francesca romano
SMSara Ciullini Mannurita
Sara Ciullini Mannurita
VBValentina Becherucci
Valentina Becherucci
EREdda Russo
Edda Russo
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework in which additional AI-detected electrophoretic features progress through analytical validity, biological validity, clinical validity, and clinical utility before being considered actionable laboratory information.

19 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
TBTiziana Biagioli
Tiziana Biagioli
LLLuisa Lanzilao
Luisa Lanzilao
FRfrancesca romano
francesca romano
SMSara Ciullini Mannurita
Sara Ciullini Mannurita
VBValentina Becherucci
Valentina Becherucci
EREdda Russo
Edda Russo
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework addressing four complementary domains: analytical validity, biological validity, clinical validity, and clinical utility. The evidence required in each domain depends on the intended claim and clinical use.